ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0937

Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study

Cal Robinson1, Rahul Chanchlani1, Anastasia Gayowsky2, Sandeep Brar3, Elizabeth Darling4, Catherine Demers4, Tapas Mondal1, Rulan Parekh5, Hsien Seow4 and Michelle Batthish1, 1McMaster Children's Hospital, Hamilton, ON, Canada, 2ICES McMaster, Hamilton, ON, Canada, 3University of California, San Fransisco, 4McMaster University, Hamilton, ON, Canada, 5University of Toronto, Toronto, Canada

Meeting: ACR Convergence 2020

Keywords: Administrative Data, Cardiovascular, Cohort Study, Pediatric rheumatology, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Plenary Session II (0934–0939)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has significantly increased in Ontario over the past two decades. However, the risk of long-term cardiovascular events in children without large CAA remains unknown. Our objectives were to: 1) determine the risk and timing of long-term cardiovascular events (diagnoses and procedures) among KD survivors; and 2) determine the risk of all-cause mortality.

Methods: We identified all children (0-18yr) surviving hospitalization with a KD diagnosis in Ontario between 1995-2018, through validated algorithms using population health administrative databases. We included only the first eligible hospitalization and excluded children previously diagnosed with KD and non-residents. KD cases were matched to 100 non-exposed controls by age, sex and index year. Follow-up continued until death or March 2019 (maximum 24 years). We determined incidence rates (per 1000 person-years (py)) and unadjusted hazard ratios (HR) for cardiovascular events, major adverse cardiac events (MACE; cardiovascular death, myocardial infarction (MI) or stroke composite) and all-cause mortality, comparing KD and non-exposed cohorts during the following time periods: 0-1yr, 1-5yr, 5-10yr and >10yr.

Results: Among 4,597 KD survivors, 746 (16.2%) experienced cardiovascular events, 79 (1.7%) MACE and 9 (0.2%) died during median 11.1-year follow-up (Table 1). The most frequent cardiovascular events among KD survivors were ischemic heart disease (231 children, 4.6 events/1000py), arrhythmias (229, 4.5/1000py), hypertension (159, 3.1/1000py) and peripheral vascular disease (107, 2.1/1000py). KD survivors were at increased risk of cardiovascular events and MACE vs. non-exposed children between 0-1yr, 1-5yr and 5-10yr, and cardiovascular events at >10yr follow-up (Table 1). KD survivors experienced cardiovascular events sooner than non-exposed children (Figure 1; Kaplan-Meier curve, log-rank p< 0.0001). Their risk of cardiovascular events was highest in the first year post-discharge (HR 14.13 [12.57-15.89]). KD survivors were at increased risk of undergoing percutaneous coronary intervention or coronary artery bypass grafting throughout follow-up (KD: 12 (0.3%) vs. non-exposed: 63 (0.01%), HR 14.68 [7.73-27.88]). KD survivors were at lower risk of mortality throughout follow-up (KD: 9 (0.2%) vs. non-exposed: 2,012 (0.4%), HR 0.42 [0.22-0.81]).

Conclusion: Children diagnosed with KD remain at increased risk of cardiovascular events for >10 years after index hospitalization. Despite the prevalence of cardiovascular disease, they have a lower risk of long-term mortality. Our findings highlight the need for cardiovascular disease surveillance and risk reduction strategies among KD survivors.

Table 1. Incidence and risk of cardiovascular events, comparing KD vs. non-exposed children at 0-1yr, 1-5yr, 5-10yr and >10yr follow-up

Figure 1. Composite cardiovascular event-free survival among KD survivors vs. non-exposed children

Figure 2. Patient survival among KD survivors vs. non-exposed children


Disclosure: C. Robinson, None; R. Chanchlani, None; A. Gayowsky, None; S. Brar, None; E. Darling, None; C. Demers, None; T. Mondal, None; R. Parekh, None; H. Seow, None; M. Batthish, Abbvie, 2.

To cite this abstract in AMA style:

Robinson C, Chanchlani R, Gayowsky A, Brar S, Darling E, Demers C, Mondal T, Parekh R, Seow H, Batthish M. Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/late-cardiovascular-outcomes-in-children-with-kawasaki-disease-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/late-cardiovascular-outcomes-in-children-with-kawasaki-disease-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology